Glura MP 1000 Tablet SR

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, leading to enhanced insulin secretion and decreased glucagon release in a glucose-dependent manner. The sustained-release formulation of Glura MP 1000 ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with Metformin.

This combination therapy is indicated for patients inadequately controlled on monotherapy or dual therapy with the individual components, aiming to achieve optimal glycemic targets while minimizing the risk of hypoglycemia. Glura MP 1000 should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose levels.

Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of pancreatitis.